arecoline has been researched along with Acute Confusional Senile Dementia in 29 studies
Arecoline: An alkaloid obtained from the betel nut (Areca catechu), fruit of a palm tree. It is an agonist at both muscarinic and nicotinic acetylcholine receptors. It is used in the form of various salts as a ganglionic stimulant, a parasympathomimetic, and a vermifuge, especially in veterinary practice. It has been used as a euphoriant in the Pacific Islands.
arecoline : A tetrahydropyridine that is 1,2,5,6-tetrahydropyridine with a methyl group at position 1, and a methoxycarbonyl group at position 3. An alkaloid found in the areca nut, it acts as an agonist of muscarinic acetylcholine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia." | 9.05 | Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. ( Christie, JE; Ferguson, J; Glen, AI; Shering, A, 1981) |
| "25 mg-1 mg), arecoline (2 and 4 mg) and saline were administered intravenously over 30 minutes in a randomized double blind design to 11 patients with a clinical diagnosis of Alzheimer presenile dementia." | 5.05 | Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. ( Christie, JE; Ferguson, J; Glen, AI; Shering, A, 1981) |
| "Many of the neurochemical changes associated with aging brain, particularly lower choline acetyltransferase and higher monoamine oxidase, occur with greater severity in senile dementia, Alzheimer's type (SDAT)." | 4.76 | Chemotherapy of cognitive disorders in geriatric subjects. ( Gershon, S; Goodnick, P, 1984) |
| " No adverse drug effects occurred." | 2.67 | Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease. ( Asthana, S; Berardi, A; Haxby, JV; Morris, PP; Raffaele, KC; Soncrant, TT, 1993) |
| "The discovery of cholinergic deficit in Alzheimer's disease (AD) patient's brain has triggered research efforts, using cholinomimetic approaches for their efficacy in AD therapy." | 1.35 | Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models. ( Chandra, JN; Malviya, M; Rangappa, KS; Sadashiva, CT; Subhash, MN, 2008) |
| "3, 1, 3, 10, or 30 mg/kg/day sc for 14 days) attenuated the AF64A-induced cognitive impairment in a dose-dependent manner, producing an inverted U-shaped dose-response function which was optimal at 1." | 1.30 | Arecoline via miniosmotic pump improves AF64A-impaired radial maze performance in rats: a possible model of Alzheimer's disease. ( Bartolomeo, AC; Boast, CA; Morris, H, 1997) |
| "Glutamatergic hypofunction occurs in Alzheimer's disease (AD)." | 1.30 | 5HT antagonists attenuate MK801-impaired radial arm maze performance in rats. ( Bartolomeo, AC; Boast, C; Morris, H; Moyer, JA, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (27.59) | 18.7374 |
| 1990's | 14 (48.28) | 18.2507 |
| 2000's | 6 (20.69) | 29.6817 |
| 2010's | 1 (3.45) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jenkins, SM | 1 |
| Wadsworth, HJ | 1 |
| Bromidge, S | 1 |
| Orlek, BS | 2 |
| Wyman, PA | 1 |
| Riley, GJ | 2 |
| Hawkins, J | 2 |
| Dunbar, PG | 1 |
| Durant, GJ | 1 |
| Rho, T | 1 |
| Ojo, B | 1 |
| Huzl, JJ | 1 |
| Smith, DA | 1 |
| el-Assadi, AA | 1 |
| Sbeih, S | 1 |
| Ngur, DO | 1 |
| Periyasamy, S | 1 |
| Bromidge, SM | 1 |
| Brown, F | 1 |
| Cassidy, F | 1 |
| Clark, MS | 1 |
| Dabbs, S | 1 |
| Hadley, MS | 1 |
| Loudon, JM | 1 |
| Naylor, CB | 1 |
| Kumar, YC | 3 |
| Malviya, M | 4 |
| Chandra, JN | 4 |
| Sadashiva, CT | 3 |
| Kumar, CS | 1 |
| Prasad, SB | 1 |
| Prasanna, DS | 1 |
| Subhash, MN | 5 |
| Rangappa, KS | 5 |
| Mythri, RB | 1 |
| Venkateshappa, C | 1 |
| Kavitha, CV | 1 |
| Thimmegowda, A | 1 |
| Asha, D | 1 |
| Pomara, N | 3 |
| Sidtis, JJ | 1 |
| Davies, P | 1 |
| Goodnick, P | 1 |
| Gershon, S | 2 |
| Brinkman, SD | 1 |
| Christie, JE | 1 |
| Shering, A | 1 |
| Ferguson, J | 1 |
| Glen, AI | 1 |
| Soncrant, TT | 6 |
| Raffaele, KC | 6 |
| Asthana, S | 7 |
| Berardi, A | 6 |
| Morris, PP | 4 |
| Haxby, JV | 4 |
| Greig, NH | 2 |
| Schapiro, MB | 4 |
| Rapoport, SI | 3 |
| Blackman, MR | 1 |
| Holloway, HW | 1 |
| Bartolomeo, AC | 2 |
| Morris, H | 2 |
| Boast, CA | 1 |
| Avery, EE | 1 |
| Baker, LD | 1 |
| Boast, C | 1 |
| Moyer, JA | 1 |
| Yang, YR | 1 |
| Chang, KC | 1 |
| Chen, CL | 1 |
| Chiu, TH | 1 |
| Stanley, M | 1 |
| LeWitt, PA | 1 |
| Galloway, M | 1 |
| Singh, R | 2 |
| Deptula, D | 2 |
| Morris, P | 1 |
| Morley, JE | 1 |
| Flood, JF | 1 |
| Nakamura, S | 1 |
| Hollander, E | 1 |
| Mohs, RC | 1 |
| Davis, KL | 1 |
| Tariot, PN | 1 |
| Cohen, RM | 1 |
| Welkowitz, JA | 1 |
| Sunderland, T | 1 |
| Newhouse, PA | 1 |
| Murphy, DL | 1 |
| Weingartner, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| M2 Receptor Measurements in Aging and in Alzheimer's Disease[NCT00001917] | 150 participants | Observational | 1999-04-30 | Completed | |||
| Cross-Cultural Adaptation of a Betel Quid Cessation Program and Evaluation of Its Effectiveness in a Malaysian High-Risk Community[NCT05782166] | 92 participants (Anticipated) | Interventional | 2024-01-02 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for arecoline and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
An update on the neurochemistry of Alzheimer disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Arecoline; Brain; Choline; Choline O-Acetyltransferase; Cho | 1983 |
Chemotherapy of cognitive disorders in geriatric subjects.
Topics: Adrenocorticotropic Hormone; Aged; Aging; Alzheimer Disease; Arecoline; Brain Chemistry; Choline; Co | 1984 |
Measurement of cholinergic drug effects on memory in Alzheimer's disease.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans | 1983 |
Potential role of muscarinic agonists in Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Arecoline; Clinical Trials as Topic; Cognition; Drug Evaluation; Drugs, In | 1997 |
Neuropeptide Y and memory processing.
Topics: Alzheimer Disease; Amygdala; Animals; Arecoline; Avoidance Learning; Feeding Behavior; Hippocampus; | 1990 |
Possible muscarinic supersensitivity in Alzheimer's disease.
Topics: Alzheimer Disease; Arecoline; Humans; Receptors, Muscarinic | 1989 |
Cholinergic approaches to the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Alanine; Alzheimer Disease; Aminopyridines; Arecoline; Clinical Trials as Topic; Hu | 1986 |
8 trials available for arecoline and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Measurement of cholinergic drug effects on memory in Alzheimer's disease.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Humans | 1983 |
Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia.
Topics: Alzheimer Disease; Arecoline; Clinical Trials as Topic; Dementia; Dose-Response Relationship, Drug; | 1981 |
Memory improvement without toxicity during chronic, low dose intravenous arecoline in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arecoline; Body Temperature; Cognition; Dose-Response Re | 1993 |
Differential response to the cholinergic agonist arecoline among different cognitive modalities in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arecoline; Attention; Cholinergic Agonists; Cognition; F | 1996 |
Clinical pharmacokinetics of arecoline in subjects with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arecoline; Cross-Over Studies; Double-Blind Method; Drug | 1996 |
Effects of long-term continuous infusion of the muscarinic cholinergic agonist arecoline on verbal memory in dementia of the Alzheimer type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Arecoline; Dose-Response Relationship, Drug; Double-Blin | 1991 |
Cholinergic approaches to the treatment of Alzheimer's disease.
Topics: 4-Aminopyridine; Alanine; Alzheimer Disease; Aminopyridines; Arecoline; Clinical Trials as Topic; Hu | 1986 |
Multiple-dose arecoline infusions in Alzheimer's disease.
Topics: Aged; Aging; Alzheimer Disease; Arecoline; Clinical Trials as Topic; Cognition; Dose-Response Relati | 1988 |
16 other studies available for arecoline and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Substituent variation in azabicyclic triazole- and tetrazole-based muscarinic receptor ligands.
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Ligands; Radioligand Assay; Rats; Receptors, Muscarinic | 1992 |
Design, synthesis, and neurochemical evaluation of 2-amino-5-(alkoxycarbonyl)-3,4,5,6-tetrahydropyridines and 2-amino-5-(alkoxycarbonyl)-1,4,5,6-tetrahydropyrimidines as M1 muscarinic receptor agonists.
Topics: Alzheimer Disease; Animals; Cerebral Cortex; Drug Design; Humans; In Vitro Techniques; Indicators an | 1994 |
Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo[2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere.
Topics: Alzheimer Disease; Animals; Binding Sites; Blood Pressure; Brain; CHO Cells; Cricetinae; Electroence | 1997 |
Effect of novel N-aryl sulfonamide substituted 3-morpholino arecoline derivatives as muscarinic receptor 1 agonists in Alzheimer's dementia models.
Topics: Alzheimer Disease; Animals; Binding, Competitive; Disease Models, Animal; Dose-Response Relationship | 2008 |
Muscarinic receptor 1 agonist activity of novel N-aryl carboxamide substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Arecoline; Cerebral Cortex; Dose-Respons | 2009 |
Synthesis and pharmacological evaluation of novel N-alkyl/aryl substituted thiazolidinone arecoline analogues as muscarinic receptor 1 agonist in Alzheimer's dementia models.
Topics: Alzheimer Disease; Animals; Arecoline; Brain; Disease Models, Animal; Male; Memory; Molecular Struct | 2009 |
Muscarinic receptor 1 agonist activity of novel N-arylthioureas substituted 3-morpholino arecoline derivatives in Alzheimer's presenile dementia models.
Topics: Alzheimer Disease; Amnesia; Animals; Arecoline; Dose-Response Relationship, Drug; Inositol 1,4,5-Tri | 2008 |
Alzheimer's disease.
Topics: Alzheimer Disease; Arecoline; Cholinergic Agonists; Humans; Neural Pathways; Receptor, Muscarinic M1 | 2010 |
Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models.
Topics: Acetylcholine; Alzheimer Disease; Animals; Arecoline; Binding, Competitive; Brain; Disease Models, A | 2008 |
Neuroendocrine responses to intravenous infusion of arecoline in patients with Alzheimer's disease.
Topics: Adrenocorticotropic Hormone; Aged; Aged, 80 and over; Alzheimer Disease; Arecoline; Arousal; beta-En | 1995 |
Arecoline via miniosmotic pump improves AF64A-impaired radial maze performance in rats: a possible model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Arecoline; Aziridines; Brain; Brain Mapping; Cerebral Cortex; Choline; D | 1997 |
5HT antagonists attenuate MK801-impaired radial arm maze performance in rats.
Topics: Alzheimer Disease; Animals; Arecoline; Cognition Disorders; Disease Models, Animal; Dizocilpine Male | 1999 |
Arecoline excites rat locus coeruleus neurons by activating the M2-muscarinic receptor.
Topics: Alzheimer Disease; Animals; Arecoline; Atropine; Cholinergic Agonists; Diamines; Hexamethonium; Locu | 2000 |
Increased CSF HVA response to arecoline challenge in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Arecoline; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Mal | 1992 |
Effects of acute infusion of the muscarinic cholinergic agonist arecoline on verbal memory and visuo-spatial function in dementia of the Alzheimer type.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Arecoline; Cognition; Female; Huma | 1991 |
[Drug therapy of Alzheimer's disease using neurotransmitter-related substances].
Topics: Alzheimer Disease; Animals; Arecoline; Brain; Cholinesterase Inhibitors; Humans; Monoamine Oxidase; | 1988 |